Revolution Medicines, Inc. Warrant (RVMD) Stock Forecast, Price Target & Predictions
RVMD Stock Forecast
Revolution Medicines, Inc. Warrant stock forecast is as follows: an average price target of $51.20 (represents a 17.16% upside from RVMD’s last price of $43.70) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.
RVMD Price Target
The average price target for Revolution Medicines, Inc. Warrant (RVMD) is $51.20 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $61.00 to $43.00. This represents a potential 17.16% upside from RVMD's last price of $43.70.
RVMD Analyst Ratings
According to 14 Wall Street analysts, Revolution Medicines, Inc. Warrant's rating consensus is 'Buy'. The analyst rating breakdown for RVMD stock is 1 'Strong Buy' (7.14%), 10 'Buy' (71.43%), 2 'Hold' (14.29%), 1 'Sell' (7.14%), and 0 'Strong Sell' (0.00%).
Revolution Medicines, Inc. Warrant Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2024 | Ami Fadia | Needham | $61.00 | $42.73 | 42.76% | 39.59% |
| Jul 15, 2024 | Robert Driscoll | Wedbush | $59.00 | $47.01 | 25.52% | 35.01% |
| Apr 19, 2024 | Ben Burnett | Stifel Nicolaus | $43.00 | $35.83 | 20.01% | -1.60% |
| Apr 12, 2024 | Ami Fadia | Needham | $46.00 | $37.41 | 22.96% | 5.26% |
| Apr 12, 2024 | Jay Olson | Oppenheimer | $45.00 | $37.41 | 20.29% | 2.97% |
| Apr 10, 2024 | Laura Prendergast | Raymond James | $48.00 | $32.99 | 45.50% | 9.84% |
| Nov 16, 2023 | Dane Leone | Raymond James | $30.00 | $21.25 | 41.18% | -31.35% |
| Dec 14, 2022 | - | Needham | $31.00 | $23.68 | 30.91% | -29.06% |
The latest Revolution Medicines, Inc. Warrant stock forecast, released on Aug 08, 2024 by Ami Fadia from Needham, set a price target of $61.00, which represents a 42.76% increase from the stock price at the time of the forecast ($42.73), and a 39.59% increase from RVMD last price ($43.70).
Revolution Medicines, Inc. Warrant Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 7 |
| Avg Price Target | - | $60.00 | $47.43 |
| Last Closing Price | $43.70 | $43.70 | $43.70 |
| Upside/Downside | -100.00% | 37.30% | 8.54% |
In the current month, the average price target of Revolution Medicines, Inc. Warrant stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Revolution Medicines, Inc. Warrant's last price of $43.70. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 08, 2024 | Needham | Buy | Buy | Hold |
| Jul 18, 2024 | Barclays | Overweight | Overweight | Hold |
| Jul 16, 2024 | Piper Sandler | Overweight | Neutral | Downgrade |
| Jul 16, 2024 | Keefe, Bruyette & Woods | Outperform | Outperform | Hold |
| Jul 16, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Jul 16, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jul 16, 2024 | Needham | Buy | Buy | Hold |
| Jul 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 15, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 15, 2024 | Wedbush | Outperform | Outperform | Hold |
Revolution Medicines, Inc. Warrant's last stock rating was published by Needham on Aug 08, 2024. The company gave RVMD a "Buy" rating, the same as its previous rate.
Revolution Medicines, Inc. Warrant Financial Forecast
Revolution Medicines, Inc. Warrant Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $742.00K | - | $3.82M | $7.01M | $15.33M | $3.36M | - | $7.58M | $9.46M | $1.10M | $8.70M | $10.13M | $8.75M | $12.66M | $10.03M | $11.55M |
| Avg Forecast | $5.73M | $1.02M | - | - | $1.20M | $1.20M | $1.20M | $1.20M | $807.69K | $807.69K | $807.69K | $1.37M | $666.67K | $750.00K | $1.56M | $3.39M | $7.80M | $6.34M | $7.02M | $8.58M | $8.99M | $8.70M | $9.38M | $9.46M | $16.78M | $14.24M | $13.36M | $13.38M |
| High Forecast | $5.73M | $1.02M | - | - | $1.20M | $1.20M | $1.20M | $1.20M | $807.69K | $923.08K | $807.69K | $1.37M | $666.67K | $750.00K | $1.56M | $3.39M | $7.80M | $6.34M | $7.02M | $15.28M | $16.00M | $15.49M | $16.71M | $16.84M | $29.88M | $25.35M | $23.79M | $23.81M |
| Low Forecast | $5.73M | $1.02M | - | - | $1.20M | $1.20M | $1.20M | $1.20M | $807.69K | $692.31K | $807.69K | $1.37M | $666.67K | $750.00K | $1.56M | $3.39M | $7.80M | $6.34M | $7.02M | $1.88M | $1.97M | $1.91M | $2.06M | $2.08M | $3.68M | $3.13M | $2.93M | $2.94M |
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.11% | - | 2.45% | 2.07% | 1.96% | 0.53% | - | 0.88% | 1.05% | 0.13% | 0.93% | 1.07% | 0.52% | 0.89% | 0.75% | 0.86% |
Revolution Medicines, Inc. Warrant's average Quarter revenue forecast for Mar 24 based on 3 analysts is $1.37M, with a low forecast of $1.37M, and a high forecast of $1.37M. RVMD's average Quarter revenue forecast represents a 85.00% increase compared to the company's last Quarter revenue of $742.00K (Dec 23).
Revolution Medicines, Inc. Warrant EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-157.27M | $-123.25M | $-108.80M | $-75.16M | $-56.63M | $-71.19M | - | $-55.36M | $-50.61M | $-51.19M | $-42.46M | $-35.49M | $-32.13M | $-25.57M | $-25.58M | $-18.63M |
| Avg Forecast | $-5.69M | $-1.02M | - | - | $-1.19M | $-1.19M | $-1.19M | $-1.19M | $-803.00K | $-803.00K | $-803.00K | $-65.75M | $-662.80K | $-745.65K | $-1.55M | $-59.77M | $-7.76M | $-40.14M | $-6.98M | $-54.34M | $-45.08M | $-42.93M | $-38.60M | $-34.80M | $-16.68M | $-23.61M | $-18.48M | $-16.56M |
| High Forecast | $-5.69M | $-1.02M | - | - | $-1.19M | $-1.19M | $-1.19M | $-1.19M | $-803.00K | $-688.29K | $-803.00K | $-52.60M | $-662.80K | $-745.65K | $-1.55M | $-47.82M | $-7.76M | $-32.11M | $-6.98M | $-43.47M | $-36.06M | $-34.35M | $-30.88M | $-27.84M | $-3.66M | $-18.89M | $-14.78M | $-13.25M |
| Low Forecast | $-5.69M | $-1.02M | - | - | $-1.19M | $-1.19M | $-1.19M | $-1.19M | $-803.00K | $-917.72K | $-803.00K | $-78.90M | $-662.80K | $-745.65K | $-1.55M | $-71.73M | $-7.76M | $-48.17M | $-6.98M | $-65.21M | $-54.09M | $-51.52M | $-46.32M | $-41.76M | $-29.70M | $-28.33M | $-22.17M | $-19.87M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 237.28% | 165.29% | 70.04% | 1.26% | 7.30% | 1.77% | - | 1.02% | 1.12% | 1.19% | 1.10% | 1.02% | 1.93% | 1.08% | 1.38% | 1.13% |
undefined analysts predict RVMD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Revolution Medicines, Inc. Warrant's previous annual EBITDA (undefined) of $NaN.
Revolution Medicines, Inc. Warrant Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-171.13M | $-108.43M | $-98.30M | $-58.51M | $-56.51M | $-73.33M | - | $-57.34M | $-52.68M | $-52.94M | $-44.30M | $-37.18M | $-34.20M | $-27.22M | $-27.21M | $-19.52M |
| Avg Forecast | $-170.36M | $-179.99M | $-177.31M | $-174.13M | $-172.82M | $-170.51M | $-167.96M | $-164.90M | $-161.94M | $-147.97M | $-127.93M | $-68.85M | $-140.84M | $-166.90M | $-135.89M | $-62.59M | $-135.75M | $-41.52M | $-140.02M | $-56.90M | $-46.91M | $-44.40M | $-40.27M | $-36.46M | $-54.21M | $-25.13M | $-19.66M | $-17.35M |
| High Forecast | $-170.36M | $-179.99M | $-177.31M | $-174.13M | $-172.82M | $-170.51M | $-167.96M | $-164.90M | $-161.94M | $-134.66M | $-127.93M | $-55.08M | $-114.64M | $-166.90M | $-135.89M | $-50.07M | $-135.75M | $-33.21M | $-140.02M | $-45.52M | $-37.53M | $-35.52M | $-32.22M | $-29.17M | $788.28K | $-20.10M | $-15.72M | $-13.88M |
| Low Forecast | $-170.36M | $-179.99M | $-177.31M | $-174.13M | $-172.82M | $-170.51M | $-167.96M | $-164.90M | $-161.94M | $-157.94M | $-127.93M | $-82.62M | $-180.15M | $-166.90M | $-135.89M | $-75.11M | $-135.75M | $-49.82M | $-140.02M | $-68.28M | $-56.30M | $-53.28M | $-48.33M | $-43.75M | $-109.22M | $-30.15M | $-23.59M | $-20.82M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.22% | 0.65% | 0.72% | 0.93% | 0.42% | 1.77% | - | 1.01% | 1.12% | 1.19% | 1.10% | 1.02% | 0.63% | 1.08% | 1.38% | 1.13% |
Revolution Medicines, Inc. Warrant's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RVMD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Revolution Medicines, Inc. Warrant SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $32.24M | $15.51M | $14.64M | $13.22M | $10.91M | $10.43M | - | $9.04M | $8.69M | $7.79M | $7.30M | $6.67M | $5.83M | $5.34M | $5.09M | $5.17M |
| Avg Forecast | $10.52M | $1.88M | - | - | $2.20M | $2.20M | $2.20M | $2.20M | $1.48M | $1.48M | $1.48M | $2.52M | $1.22M | $1.38M | $2.87M | $6.23M | $14.33M | $6.11M | $12.89M | $15.77M | $7.74M | $6.53M | $6.63M | $6.54M | $30.82M | $4.93M | $3.68M | $4.60M |
| High Forecast | $10.52M | $1.88M | - | - | $2.20M | $2.20M | $2.20M | $2.20M | $1.48M | $1.70M | $1.48M | $2.52M | $1.22M | $1.38M | $2.87M | $6.23M | $14.33M | $7.33M | $12.89M | $28.07M | $9.29M | $7.84M | $7.96M | $7.85M | $54.87M | $5.92M | $4.41M | $5.52M |
| Low Forecast | $10.52M | $1.88M | - | - | $2.20M | $2.20M | $2.20M | $2.20M | $1.48M | $1.27M | $1.48M | $2.52M | $1.22M | $1.38M | $2.87M | $6.23M | $14.33M | $4.89M | $12.89M | $3.46M | $6.19M | $5.23M | $5.31M | $5.23M | $6.77M | $3.94M | $2.94M | $3.68M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 26.33% | 11.26% | 5.10% | 2.12% | 0.76% | 1.71% | - | 0.57% | 1.12% | 1.19% | 1.10% | 1.02% | 0.19% | 1.08% | 1.38% | 1.13% |
Revolution Medicines, Inc. Warrant's average Quarter SG&A projection for Mar 24 is $2.52M, based on 3 Wall Street analysts, with a range of $2.52M to $2.52M. The forecast indicates a -92.18% fall compared to RVMD last annual SG&A of $32.24M (Dec 23).
Revolution Medicines, Inc. Warrant EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-0.00 | $-0.62 | $-0.63 | $-0.87 | - | $-0.77 | $-0.71 | $-0.72 | $-0.60 | $-0.53 | $-0.52 | $-0.42 | $-0.46 | $-0.74 |
| Avg Forecast | $-1.03 | $-1.09 | $-1.07 | $-1.05 | $-1.05 | $-1.03 | $-1.02 | $-1.00 | $-0.98 | $-0.90 | $-0.77 | $-0.75 | $-0.85 | $-1.01 | $-0.82 | $-0.80 | $-0.82 | $-0.84 | $-0.85 | $-0.78 | $-0.64 | $-0.63 | $-0.56 | $-0.52 | $-0.38 | $-0.39 | $-0.36 | $-0.33 |
| High Forecast | $-1.03 | $-1.09 | $-1.07 | $-1.05 | $-1.05 | $-1.03 | $-1.02 | $-1.00 | $-0.98 | $-0.82 | $-0.77 | $-0.75 | $-0.69 | $-1.01 | $-0.82 | $-0.80 | $-0.82 | $-0.84 | $-0.85 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | - |
| Low Forecast | $-1.03 | $-1.09 | $-1.07 | $-1.05 | $-1.05 | $-1.03 | $-1.02 | $-1.00 | $-0.98 | $-0.96 | $-0.77 | $-0.75 | $-1.09 | $-1.01 | $-0.82 | $-0.80 | $-0.82 | $-0.84 | $-0.85 | $-1.56 | $-1.29 | $-1.26 | $-1.13 | $-1.06 | $-0.77 | $-0.79 | $-0.73 | $-0.67 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.77% | 0.77% | 1.03% | - | 0.99% | 1.11% | 1.15% | 1.07% | 1.01% | 1.35% | 1.07% | 1.27% | 2.22% |
According to undefined Wall Street analysts, Revolution Medicines, Inc. Warrant's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RVMD previous annual EPS of $NaN (undefined).
Revolution Medicines, Inc. Warrant Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| SANA | Sana Bio | $4.47 | $12.00 | 168.46% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| CCCC | C4 Therapeutics | $6.44 | $11.33 | 75.93% | Hold |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| RNA | Avidity Biosciences | $41.71 | $50.00 | 19.88% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| NRIX | Nurix Therapeutics | $24.80 | $27.57 | 11.17% | Buy |
| KYMR | Kymera Therapeutics | $46.08 | $51.10 | 10.89% | Buy |
| PTGX | Protagonist Therapeutics | $47.02 | $50.00 | 6.34% | Buy |
| AGIO | Agios Pharmaceuticals | $46.69 | $47.50 | 1.73% | Buy |
RVMD Forecast FAQ
Is Revolution Medicines, Inc. Warrant a good buy?
Yes, according to 14 Wall Street analysts, Revolution Medicines, Inc. Warrant (RVMD) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 10 'Buy' recommendations, accounting for 78.57% of RVMD's total ratings.
What is RVMD's price target?
Revolution Medicines, Inc. Warrant (RVMD) average price target is $51.2 with a range of $43 to $61, implying a 17.16% from its last price of $43.7. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Revolution Medicines, Inc. Warrant stock go up soon?
According to Wall Street analysts' prediction for RVMD stock, the company can go up by 17.16% (from the last price of $43.7 to the average price target of $51.2), up by 39.59% based on the highest stock price target, and down by -1.60% based on the lowest stock price target.
Can Revolution Medicines, Inc. Warrant stock reach $70?
RVMD's average twelve months analyst stock price target of $51.2 does not support the claim that Revolution Medicines, Inc. Warrant can reach $70 in the near future.
What are Revolution Medicines, Inc. Warrant's analysts' financial forecasts?
Revolution Medicines, Inc. Warrant's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $4.8M (high $4.8M, low $4.8M), average EBITDA is $-4.772M (high $-4.772M, low $-4.772M), average net income is $-676M (high $-676M, low $-676M), average SG&A $8.82M (high $8.82M, low $8.82M), and average EPS is $-4.095 (high $-4.095, low $-4.095). RVMD's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $6.75M (high $6.75M, low $6.75M), average EBITDA is $-6.708M (high $-6.708M, low $-6.708M), average net income is $-702M (high $-702M, low $-702M), average SG&A $12.39M (high $12.39M, low $12.39M), and average EPS is $-4.25 (high $-4.25, low $-4.25).
Did the RVMD's actual financial results beat the analysts' financial forecasts?
Based on Revolution Medicines, Inc. Warrant's last annual report (Dec 2023), the company's revenue was $11.58M, beating the average analysts forecast of $6.37M by 81.80%. Apple's EBITDA was $-487M, beating the average prediction of $-62.736M by 676.57%. The company's net income was $-436M, missing the average estimation of $-506M by -13.80%. Apple's SG&A was $75.62M, beating the average forecast of $11.7M by 546.37%. Lastly, the company's EPS was $-0.0039, missing the average prediction of $-3.49 by -99.89%. In terms of the last quarterly report (Dec 2023), Revolution Medicines, Inc. Warrant's revenue was $742K, beating the average analysts' forecast of $666.67K by 11.30%. The company's EBITDA was $-157M, beating the average prediction of $-663K by 23628.04%. Revolution Medicines, Inc. Warrant's net income was $-171M, beating the average estimation of $-141M by 21.50%. The company's SG&A was $32.24M, beating the average forecast of $1.22M by 2533.25%. Lastly, the company's EPS was $-0.0015, missing the average prediction of $-0.853 by -99.82%